Amgen’s Blincyto (blinatumomab) should receive National Health Service funding in a rare form of leukaemia, NICE has said – and commissioners have also okayed its use in a paediatric blood ...

Blincyto is a key contributor to Amgen’s top line and generated sales of $861 million in 2023, rising 48% year over year. Amgen’s other BiTE therapy, which was recently approved in May, was ...

The blincyto market size is expected to see strong growth in the next few years. It will grow to $1,022.10 million in 2029 at a compound annual growth rate (CAGR) of 5.9%.” - The Business ...